当前位置： 阿仪网 > 生物试剂/抗体/细胞 > 细胞生物学 > 细胞/细胞株 > 上海富衡生物科技有限公司 > 产品展示 > 细胞库 > 人源细胞 > 人恶性胶质瘤细胞U87 MGFH0162
人恶性胶质瘤细胞U87 MGFH0162
价格：￥电议
品牌名称：富衡型号：FH0162 原产地：中国大陆 更新时间：2026/10/21 7:56:21
产品摘要：U87 MG细胞系由科学家J. Ponten及其同事在1966年至1969年间，从一名44岁男性患者的恶性神经胶质瘤（星形胶质母细胞瘤）组织中分离建立。U87 MG细胞是神经科学和肿瘤学研究领域中应用最广泛的人类胶质母细胞瘤模型之一。
支付方式：
- 支付宝 微信 银行转账
产品完善度： 访问次数：963
企业档案
会员类型：旗舰版
已获得阿仪网信誉 等级评定
61成长值
(0 -40)基础信誉积累，可浏览访问
(41-90)良好信誉积累，可接洽商谈
(91+ )优质信誉积累，可持续信赖
阿仪网旗舰版会员：3年
工商认证 【已认证】
最后认证时间：
注册号： 【已认证】
法人代表： 【已认证】
参观次数：629025
详细内容
| 产品名称 | 人恶性胶质瘤细胞；U87 MG (STR) |
|---|---|
| 品牌 | FuHeng |
| 英文名 | U87 MG (STR) |
| 货号 | FH0162 |
| 规格 | 1×10⁶cells/T25培养瓶 |
| 价格 | 1400.0 |
| 培养 | MEM+10%FBS |
| 别称 | U-87MG; U-87 MG; U-87-MG; U87-MG; U87MG; U-87; U87; 87 MG; 87MG; U-87MG ATCC |
| 形态特征 | 上皮细胞样 |
| 生长特性 | 贴壁生长 |
| 培养条件 | 气相：空气，95%；CO2,5%温度：37℃ |
| 传代方法 | 1:2传代 |
| 组织来源 | 多形性胶质母细胞瘤 |
| 细胞简介 | 人恶性胶质瘤细胞；U87 MG (STR) |
| 特征特性 | 该细胞系由Ponten J等建立，源于恶性神经胶质瘤。裸鼠皮下接种可成瘤。 |
| 培养基 | U87 MG完全培养基 |
富衡相关文献
| 论文标题 | DOI | 发表时间 | 期刊 | 影响因子 | 作者列表 |
| Integrated tranｓcriptomic analysis reveals mitochondrial dysregulation and macrophage heterogeneity associated with MTHFD2 in glioblastoma | 10.1016/j.brainresbull.2026.111758 | 2026-01-31 | BRAIN RESEARCH BULLETIN | 3.7 | Binfeng Tu, Yulong Ji, Zilong Tan, Shiqi Cheng, Yan Zhang |
| Metalloporphyrin organic ｆframework oxygen-generators enable tumour-targeted photodynamic therapy and ｍmbedbolic reprogramming for enhanced glioblastoma treatment | 10.1016/j.jcis.2025.139521 | 2025-11-22 | JOURNAL OF COLLOID AND INTERFACE SCIENCE | 9.7 | Jiahe Hu, Xiuwei Yan, Jiaoyan He, Yapeng Niu, Lihui Zhou, Mo Geng, Tao Jia, Lili Feng, Wenchao Fu, Shaoshan Hu |
| Multimerin-1 modulates macrophage M2 polarization and enhances tumor cell stemness in glioblastoma | 10.1080/01616412.2025.2520060 | 2025-06-21 | NEUROLOGICAL RESEARCH | 1.5 | Chao Huang, Xue-Bin Yu, Yong-Zhi Zhou, Xiao-Bing Zhang, Chang-Ming Dong, Wu-Qiao Bao |
| The alternatively spliced diacylglycerol kinase gamma-Δ exon13 tranｓcript generated under hypoxia promotes glioblastoma progression | 10.32604/or.2024.055102 | 2025-04-18 | ONCOLOGY RESEARCH | 4.1 | MING YANG, LIANGZHAO CHU, SHUKAI LIN, HAN PENG, NIYA LONG, KAYA XU, HUA YANG, FENG HAN, JIAN LIU |
| A novel trifluoromethyl quinoline derivative targeting SGK1 inducing autophagy and apoptosis via regulating mTOR/FOXO3a pathway in glioblastoma | 10.1016/j.arabjc.2024.105909 | 2024-07-16 | Arabian Journal of Chemistry | 5.3 | Yu-feng Xiong, Cheng Li, Jia Yu, Xiaozhong Chen, Sha Cheng, Xin-yu Liu, Bi-xue Xu, Xiao Hu, Guang-can Xu, Heng Luo |
| YTHDF1 promotes the viability and self‑renewal of glioma stem cells by enhancing LINC00900 stability | 10.3892/ijo.2024.5641 | 2024-03-28 | INTERNATIONAL JOURNAL OF ONCOLOGY | 4.5 | Yuanhai Zhang, Yi Zhu, Yating Zhang, Zixiang Liu, Xudong Zhao |
| HNF1A induces glioblastoma by upregulating EPS8 and activating PI3K/AKT signaling pathway | 10.1016/j.bcp.2024.116133 | 2024-03-15 | BIOCHEMICAL PHARMACOLOGY | 5.3 | Gang Yang, Fei Su, Bin-xiao Han, Hong-xin Su, Chen-hao Guo, Shao-hua Yu, Quan-lin Guan, Xiao-ming Hou |
| Effect of gold-conjugated resveratrol nanoparticles on glioma cells and its underlying mechanism | 10.3233/BME-230171 | 2024-02-22 | BIO-MEDICAL MATERIALS AND ENGINEERING | 1.0 | Liu Xiaojiang, Guo Zongfeng, Li Jun, Wu Demo, Liu Zhongping, Guan Cheng, Guan Yixiang, Lu Xiaomin |
| SENP1-mediated SUMOylation of SIRT1 affects glioma development through the NF-κB pathway | 10.1016/j.yexcr.2023.113822 | 2023-10-21 | EXPERIMENTAL CELL RESEARCH | 3.7 | Xin Liu, Shenglin Zhang, Yi Dong, Yunpeng Xie, Qingshan Li |
| Knockdown of T Cell Immunoglobulin and Mucin 1 (Tim-1) Suppresses Glioma Progression Through Inhibition of the Cytokine-PI3K/AKT Pathway | 10.2147/OTT.S255117 | 2023-04-07 | OncoTargets and Therapy | 4.0 | Peng Zhou, Maoxing Fei, Yanling Han, Mengliang Zhou, Handong Wang |
| Preliminary evaluation of a 64Cu-labeled DNA aptamer for PET imaging of glioblastoma | 10.1007/s10967-023-08835-2 | 2023-02-22 | JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY | 1.6 | Li Pinghui, Wang Chunmei, Wang Wenrui, Duan Xiaoyan, Li Jianbo |
| Antitumor mechanism of kangliu pill on gliomas in mice through PI3K-Akt signaling pathway | 10.1016/j.jep.2023.116252 | 2023-02-11 | JOURNAL OF ETHNOPHARMACOLOGY | 5.4 | Fei Chen, Jing-Jing Cui, De-Chun Jiang, Hai-Zheng Wang, Wei Zhuang, Ying-Nan Feng, Xiao-Lan Lin, Sheng-Yan Xi |
| Microwave-assisted extraction, structural elucidation, and in vitro anti-glioma and immunostimulatory activity of polysaccharide from Panax ginseng C. A. Meyer | 10.1016/j.indcrop.2022.115729 | 2022-10-10 | INDUSTRIAL CROPS AND PRODUCTS | 6.449 | Dongxue Cao, Enwei Wei, Zeyu Wang, Zhengyu Hu, Ling Qi, Hongli Zhou, Jingli Zhao |
| TRAF3IP3 promotes glioma progression through the ERK signaling pathway | 10.3389/fonc.2022.776834 | 2022-09-16 | Frontiers in Oncology | 5.738 | Lin Qi, Chen Zhen, Shen Zhao-Li, Xue Fei, Qin Jia-Jun, Kang Xi-Peng, Chen Zhong-Rong, Xia Zhong -Yuan, Gao Liang, Chen Xian-Zhen |
| Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma | 10.1016/j.acthis.2022.151856 | 2022-01-22 | ACTA HISTOCHEMICA | 2.147 | Chaohong Huang, Yujie He, Jianwu Sun, Qian Yuan, Shuyi Li, Huan Hou, Kui Su, Changhong Ke, Zhiyun Du, Zhengqiang Yuan |
| Downregulation of Tim-1 inhibits the proliferation, migration and invasion of glioblastoma cells via the miR-133a/TGFBR1 axis and the restriction of Wnt/β-catenin pathway | 10.1186/s12935-021-02036-1 | 2021-07-05 | Cancer Cell International | 5.722 | Wei Li, Peng Ya, Shao Naiyuan, Zhou Peng |
| Inhibition of Cathepsin S Restores TGF-β-induced Epithelial-to-mesenchymal Transition and Tight Junction Turnover in Glioblastoma Cells | 10.7150/jca.50631 | 2021-01-15 | Journal of Cancer | 4.207 | Li Wei, Naiyuan Shao, Ya Peng, Peng Zhou |
| Identification of KIF15 as a potential therapeutic target and prognostic factor for glioma | 10.3892/or.2020.7510 | 2020-02-21 | ONCOLOGY REPORTS | 3.417 | Qilong Wang, Bin Han, Wu Huang, Chunjian Qi, Fang Liu |
上海衡生物科技有限公司
上海富衡生物科技有限公司（以下简称“富衡”）是主要从事生物科技，医药科技领域内的技术开发，技术咨询，技术服务的高新技术企业。是一家专注于细胞相关技术，服务及产品的高科技生命科学和生物技术领域企业。
富衡提供专业的细胞鉴定服务（采用ATCC细胞鉴定准－－STR基因分型技术），并建立完善鉴定，种类齐全的细胞资源库，能为广大科研工作者在发表高质量文章时提供可靠的“细胞鉴定依据”。公司拥有一个蓬勃朝气的年轻团队，不断进取，我们密切注视细胞技术领域的发展，并且于员工的技术和素质培训。团队中博士硕士以上学历人士达80％，有很强的技术支持及研发能力。
专注于细胞培养 PARTNERS 合作伙伴
热门标签：人恶性胶质瘤细胞U87,MG,U87,MG,U87,MG细胞
